Rush University Medical Center, Psychiatric Research Clinical Center, 2150 West Harrison, Chicago, IL 60612, USA.
Expert Opin Pharmacother. 2012 Aug;13(11):1645-52. doi: 10.1517/14656566.2012.681377. Epub 2012 May 3.
Bipolar disorder is characterized by mood instability, which can be challenging to manage. First-line pharmacological approaches usually involve lithium, anticonvulsants and antipsychotics. Over the past fifteen years, several second-generation antipsychotics have demonstrated benefits for various phases of this disorder.
This article examines the pharmacodynamics and pharmacokinetics of quetiapine ; its evidence base as an acute and maintenance monotherapy or adjunctive therapy for bipolar manic or mixed episodes is also discussed, along with the related issues of its safety and tolerability.
In the context of bipolar disorder, quetiapine is the only agent approved as a monotherapy or adjunct therapy for acute manic/mixed episodes in adults and adolescents; as a monotherapy for acute depressive episodes in adults; and as an adjunctive maintenance therapy for bipolar I and II disorder in adults. In addition to its antipsychotic properties, this broad mood-stabilizing potential may simplify the management of select patients.
双相情感障碍的特征是情绪不稳定，这很难控制。一线药物治疗方法通常包括锂、抗惊厥药和抗精神病药。在过去的十五年中，几种第二代抗精神病药已被证明对这种疾病的各个阶段都有好处。
本文研究了喹硫平的药效学和药代动力学; 还讨论了其作为急性和维持期单药或辅助治疗双相躁狂或混合发作的证据基础，以及与安全性和耐受性相关的问题。
在双相情感障碍的背景下，喹硫平是唯一一种被批准用于成人和青少年急性躁狂/混合发作的单药或辅助治疗药物; 用于成人急性抑郁发作的单药治疗; 以及成人 I 型和 II 型双相障碍的辅助维持治疗。除了其抗精神病特性外，这种广泛的情绪稳定潜力可能会简化某些患者的管理。
